

fraction do not normally express the GABA_BR1/R2 receptor, with the compound under conditions suitable for binding, and detecting specific binding of the chemical compound to the GABA_BR1/R2 receptor or membrane fraction.--

- 191. (New) The process of claim 190, wherein the GABA_BR1/R2 receptor comprises a GABA_BR2 polypeptide which has the same amino acid sequence as that encoded by the plasmid BO-55 (ATCC Accession No. 209104).--
- 192. (New) The process of claim 190, wherein the GABA_BR1/R2 receptor comprises a GABA_BR2 polypeptide which has the same amino acid sequence as that shown in Figures 23A-23D (Seq. ID No. 47).-- F
- B₁
--193. (New) The process of claims 190, wherein the GABA_BR1/R2 receptor comprises a GABA_BR2 polypeptide which has the same amino acid sequence as that encoded by the plasmid pEXJT3T7-hGABAB2 (ATCC Accession No. 203515).--
- 194. (New) A process of claim 190, wherein the cell is an insect cell or a mammalian cell.--
- 195. (New) A process of claim 194, wherein the mammalian cell is nonneuronal in origin.--
- 196. (New) A process of claim 195, wherein the nonneuronal cell is a COS-7 cell, 293 human embryonic kidney cell, a CHO cell, a NIH-3T3 cell a mouse Y1 cell or LM(tk-) cell.--
- 197. (New) A process involving competitive binding for identifying a chemical compound which specifically binds to a mammalian GABA_BR1/R2 receptor which

comprises separately contacting cells expressing on their cell surface the GABA_BR1/R2 receptor or a membrane fraction from such cells, wherein such cells or membrane fraction do not normally express the GABA_BR1/R2 receptor, with both the chemical compound and a second chemical compound known to bind to the receptor, and with only the second chemical compound, under conditions suitable for binding of both compounds, and detecting specific binding of the chemical compound to the GABA_BR1/R2 receptor, a decrease in the binding of the second chemical compound to the GABA_BR1/R2 receptor in the presence of the chemical compound indicating that the chemical compound binds to the GABA_BR1/R2 receptor or membrane fraction.--

B1

F

- 198. (New) The process of claim 197, wherein the GABA_BR1/R2 receptor comprises a GABA_BR2 polypeptide which has the same amino acid sequence as that encoded by plasmid BO-55 (ATCC Accession No. 209104).--
- 199. (New) The process of claim 197, wherein the GABA_BR1/R2 receptor comprises a GABA_BR2 polypeptide which has the same amino acid sequence as that shown in Figures 23A-23D (Seq. ID No. 47).--
- 200. (New) The process of claim 197, wherein the GABA_BR1/R2 receptor comprises a GABA_BR2 polypeptide which has the same amino acid sequence as that encoded by plasmid pEXJT3T7-hGABAB2 (ATCC Accession No. 203515). --
- 201. (New) The process of claim 197, wherein the cell is an insect cell or a mammalian cell.--
- 202. (New) The process of claim 201, wherein the mammalian

cell is nonneuronal in origin.--

- 203. (New) The process of claim 202, wherein the nonneuronal cell is a COS-7 cell, 293 human embryonic kidney cell, a CHO cell, a NIH-3T3 cell a mouse Y1 cell or LM(tk-) cell.--
- 204. (New) A method of screening a plurality of chemical compounds not known to bind to a mammalian GABA_BR1/R2 receptor to identify a compound which specifically binds to the GABA_BR1/R2 receptor, which comprises
- (a) contacting cells containing nucleic acid encoding and expressing on their cell surface the GABA_BR1/R2 receptor or a membrane fraction from such cells, wherein such cells or membrane fraction do not normally express the GABA_BR1/R2 receptor, with a compound known to bind specifically to the GABA_BR1/R2 receptor;
- (b) contacting the same cells or membrane fraction as in step (a) with the plurality of compounds not known to bind specifically to the GABA_BR1/R2 receptor, under conditions permitting binding of compounds known to bind the GABA_BR1/R2 receptor;
- (c) determining whether the binding of the compound known to bind specifically to the GABA_BR1/R2 receptor is reduced in the presence of the plurality of the compounds, relative to the binding of the compound in the absence of the plurality of compounds, and if the binding is reduced;
- (d) separately determining the extent of binding to

the GABA_BR1/R2 receptor of each compound included in the plurality of compounds, so as to thereby identify the compound or compounds present in such plurality of compounds which specifically binds to the GABA_BR1/R2 receptor.--

--205. (New) A method of claim 204, wherein the cell is a mammalian cell.--

--206. (New) A method of claim 205, wherein the mammalian cell is non-neuronal in origin.--

B1 --207. (New) The method of claim 206, wherein the non-neuronal cell is a COS-7 cell, a 293 human embryonic kidney cell, a LM(tk-) cell, a CHO cell, a mouse Y1 cell or an NIH-3T3 cell.--

Mac17 --208. (New) A process for determining whether a chemical compound is a mammalian GABA_BR1/R2 receptor agonist which comprises contacting cells with the compound under conditions permitting the activation of the GABA_BR1/R2 receptor, and detecting an increase in GABA_BR1/R2 receptor activity, so as to thereby determine whether the compound is a GABA_BR1/R2 receptor agonist.--

--209. (New) A process for determining whether a chemical compound is a mammalian GABA_BR1/R2 receptor antagonist which comprises contacting cells containing nucleic acid encoding and expressing on their cell surface the GABA_BR1/R2 receptor, wherein such cells do not normally express the GABA_BR1/R2 receptor, with the compound in the presence of a known GABA_BR1/R2 receptor agonist, under conditions permitting the activation of the GABA_BR1/R2 receptor, and detecting a decrease in

~~GABA_BR1/R2 receptor activity, so as to thereby
determine whether the compound is a GABA_BR1/R2 receptor
antagonist.--~~

Sub F2 } --210. (New) A process of claim 208 or 209, wherein the cells
additionally express nucleic acid encoding GIRK1 and
GIRK4.-- ~~F~~

--211. (New) A pharmaceutical composition which comprises an
amount of a GABA_BR1/R2 receptor agonist determined to
be an agonist by the process of claim 208 effective to
increase activity of a GABA_BR1/R2 receptor and a
pharmaceutically acceptable carrier.--

B1 --212. (New) A pharmaceutical composition which comprises an
amount of a GABA_BR1/R2 receptor antagonist determined
to be an antagonist the process of claim 209 effective
to reduce activity of a GABA_BR1/R2 receptor and a
pharmaceutically acceptable carrier.-- ~~F~~

--213. (New) A process for determining whether a chemical
compound activates a mammalian GABA_BR1/R2 receptor,
which comprises contacting cells producing a second
messenger response and expressing on their cell
surface the GABA_BR1/R2 receptor, wherein such cells do
not normally express the GABA_BR1/R2 receptor, with the
chemical compound under conditions suitable for
activation of the GABA_BR1/R2 receptor, and measuring
the second messenger response in the presence and in
the absence of the chemical compound, a change in the
second messenger response in the presence of the
chemical compound indicating that the compound
activates the GABA_BR1/R2 receptor.--

--214. (New) The process of claim 213, wherein the second

messenger response comprises potassium channel activation and the change in second messenger is an increase in the level of potassium current.--

bi
--215. (New) A process for determining whether a chemical compound inhibits activation of a mammalian GABA_BR1/R2 receptor, which comprises separately contacting cells producing a second messenger response and expressing on their cell surface the GABA_BR1/R2 receptor, wherein such cells do not normally express the GABA_BR1/R2 receptor, with both the chemical compound and a second chemical compound known to activate the GABA_BR1/R2 receptor, and with only the second chemical compound, under conditions suitable for activation of the GABA_BR1/R2 receptor, and measuring the second messenger response in the presence of only the second chemical compound and in the presence of both the second chemical compound and the chemical compound, a smaller change in the second messenger response in the presence of both the chemical compound and the second chemical compound than in the presence of only the second chemical compound indicating that the chemical compound inhibits activation of the GABA_BR1/R2 receptor.--

--216. (New) The process of claim 215, wherein the second messenger response comprises potassium channel activation and the change in second messenger response is a smaller increase in the level of inward potassium current in the presence of both the chemical compound and the second chemical compound than in the presence of only the second chemical compound.--

--217. (New) The process of claim 216, wherein the GABA_BR1/R2 receptor comprises a GABA_BR2 polypeptide which has the

same amino acid sequence as that encoded by the
plasmid BO-55 (ATCC Accession No. 209104).--

- 218. (New) The process of claim 216, wherein the GABA_BR1/R2 receptor comprises a GABA_BR2 polypeptide which has the same amino acid sequence as that shown in Figures 4A-4D (Seq. ID No. 4).-- F
- 219. (New) The process of claim 216, wherein the GABA_BR1/R2 receptor comprises a GABA_BR2 polypeptide which has the same amino acid sequence as that shown in Figures 23A-23D (Seq. ID No. 47).--
- 220. (New) The process of claim 216, wherein the GABA_BR1/R2 receptor comprises a GABA_BR2 polypeptide which has the same amino acid sequence as that encoded by the plasmid pEXT3T7-hGABAB2 (ATCC Accession No. 203519).--

- B1
- 221. (New) The process of any one of claims 213-216, wherein the cell is an insect cell or a mammalian cell.--

- 222. (New) The process of claim 221, wherein the mammalian cell is nonneuronal in origin.--
- 223. (New) The process of claim 222, wherein the nonneuronal cell is a COS-7 cell, CHO cell, 293 human embryonic kidney cell, NIH-3T3 cell or LM(tk-) cell.--
- 224. (New) A method of screening a plurality of chemical compounds not known to activate a mammalian GABA_BR1/R2 receptor to identify a compound which activates the GABA_BR1/R2 receptor which comprises:

(a) contacting cells containing nucleic acid encoding

JMC 37

and expressing on their cell surface the GABA_BR1/R2 receptor, wherein such cells do not normally express the GABA_BR1/R2 receptor, with the plurality of compounds not known to activate the GABA_BR1/R2 receptor, under conditions permitting activation of the GABA_BR1/R2 receptor;

- (b) determining whether the activity of the GABA_BR1/R2 receptor is increased in the presence of the compounds, and if it is increased;
- (c) separately determining whether the activation of the GABA_BR1/R2 receptor is increased by each compound included in the plurality of compounds, so as to thereby identify the compound or compounds present in such plurality of compounds which activates the GABA_BR1/R2 receptor.

Sub F5

--225.

~~(New)~~ The process of claim 224, wherein the cells express nucleic acid encoding GIRK1 and GIRK4.--

--226.

~~(New)~~ A method of screening a plurality of chemical compounds not known to inhibit the activation of a mammalian GABA_BR1/R2 receptor to identify a compound which inhibits the activation of the GABA_BR1/R2 receptor, which comprises:

- (a) contacting cells containing nucleic acid encoding and expressing on their cell surface the GABA_BR1/R2 receptor, wherein such cells do not normally express the GABA_BR1/R2 receptor, with the plurality of compounds in the presence of a known GABA_BR1/R2 receptor agonist, under conditions permitting activation of the GABA_BR1/R2 receptor;

(b) determining whether the activation of the GABA_AR1/R2 receptor is reduced in the presence of the plurality of compounds, relative to the activation of the GABA_AR1/R2 receptor in the absence of the plurality of compounds, and if it is reduced; F

(c) separately determining the inhibition of activation of the GABA_AR1/R2 receptor for each compound included in the plurality of compounds, so as to thereby identify the compound or compounds present in such a plurality of compounds which inhibits the activation of the GABA_AR1/R2 receptor.--

--227. (New) The process of claim 226, wherein the cells express nucleic acid encoding GIRK1 and GIRK4.--

Sub F6
--228. (New) A method of any one of claims 224, 225, 226 or 227, wherein the cell is a mammalian cell.--

--229. (New) A method of claim 228, wherein the mammalian cell is non-neuronal in origin.--

Sub F8
--230. (New) The method of claim 229, wherein the non-neuronal cell is a COS-7 cell, a 293 human embryonic kidney cell, a LM(tk-) cell or an NIH-3T3 cell.--

Sub C4
--231. (New) A process for determining whether a chemical compound is a mammalian GABA_AR1/R2 receptor agonist, which comprises preparing a membrane fraction from cells which comprise nucleic acid encoding and expressing on their cell surface the GABA_AR1/R2 receptor, wherein such cells do not normally express the GABA_AR1/R2 receptor, separately contacting the

Applicants: Kenneth A. Jones, et al.
U.S. Serial No. 09/211,755
Filed: December 15, 1998
Page 13

membrane fraction with both the chemical compound and GTPyS, and with only GTPyS, under conditions permitting the activation of the GABA_BR1/R2 receptor, and detecting GTPyS binding to the membrane fraction, an increase in GTPyS binding in the presence of the compound indicating that the chemical compound activates the GABA_BR1/R2 receptor.--

--232.

(New) A process for determining whether a chemical compound is a mammalian GABA_BR1/R2 receptor antagonist, which comprises preparing a membrane fraction from cells which comprise nucleic acid encoding and expressing on their cell surface the GABA_BR1/R2 receptor, wherein such cells do not normally express the GABA_BR1/R2 receptor, separately contacting the membrane fraction with the chemical compound, GTPyS and a second chemical compound known to activate the GABA_BR1/R2 receptor, with GTPyS and only the second compound, and with GTPyS alone, under conditions permitting the activation of the GABA_BR1/R2 receptor, detecting GTPyS binding to each membrane fraction, and comparing the increase in GTPyS binding in the presence of the compound and the second compound relative to the binding of GTPyS alone, to the increase in GTPyS binding in the presence of the second chemical compound known to activate the GABA_BR1/R2 receptor relative to the binding of GTPyS alone, a smaller increase in GTPyS binding in the presence of the compound and the second compound indicating that the compound is a GABA_BR1/R2 receptor antagonist.--

--233.

(New) The process of claim 231 or 232, wherein the GABA_BR1/R2 receptor comprises a GABA_BR2 polypeptide which has the same amino acid sequence as that encoded

by the plasmid BO-55 (ATCC Accession No. 209104).--

--234. (New) The process of claim 231 or 232, wherein the GABA_AR1/R2 receptor comprises a GABA_AR2 polypeptide which has the same amino acid sequence as that shown in Figures 4A-4D (Seq. ID No. 4).--

Sub F7
cont. } --235. (New) The process of claim 231 or 232, wherein the GABA_AR1/R2 receptor comprises a GABA_AR2 polypeptide which has the same amino acid sequence as that encoded by the plasmid pEXJT3T7-hGABAB2 (ATCC Accession No. 203515).--

F

--236. (New) The process of claim 231 or 232, wherein the GABA_AR1/R2 receptor comprises a GABA_AR2 polypeptide which has the same amino acid sequence as that shown in Figures 23A-23D (Seq. ID No. 47).--

--237. (New) The process of claim 231 or 232, wherein the cell is an insect cell or a mammalian cell.--

--238. (New) The process of claim 237, wherein the mammalian cell is nonneuronal in origin.--

--239. (New) The process of claim 238, wherein the nonneuronal cell is a COS-7 cell, CHO cell, 293 human embryonic kidney cell, NIH-3T3 cell or LM(tk-) cell.--

Sub H1 } --240. (New) The process of claim 239, wherein the compound was not previously known to be an agonist or antagonist of a GABA_AR1/R2 receptor.--

--241. (New) A compound determined to be an agonist or antagonist of a GABA_AR1/R2 receptor by the process of claim 240.--

- B1
- 242. (New) A process for making a composition of matter which specifically binds to a GABA_AR1/R2 receptor which comprises identifying a chemical compound using the process of any of claims 190, 197 or 204 and then synthesizing the chemical compound or a novel structural and functional analog or homolog thereof.--
- 243. (New) A process for making a composition of matter which specifically binds to a GABA_AR1/R2 receptor which comprises identifying a chemical compound using the process of any of claims 208, 213, or 224 and then synthesizing the chemical compound or a novel structural and functional analog or homolog thereof.--
- 244. (New) A process for making a composition of matter which specifically binds to a GABA_AR1/R2 receptor which comprises identifying a chemical compound using the process of any of claims 209, 215, or 226 and then synthesizing the chemical compound or a novel structural and functional analog or homolog thereof.--
- 245. (New) The process of any of claims 242, 243, or 244, wherein the GABA_AR1/R2 receptor is a human GABA_AR1/R2 receptor.--
- 246. (New) A process for preparing a pharmaceutical composition which comprises admixing a pharmaceutically acceptable carrier and a pharmaceutically acceptable amount of a chemical compound identified by the process of any of claims 190, 197 or 204 or a novel structural and functional analog or homolog thereof.--
- 247. (New) A process for preparing a pharmaceutical composition which comprises admixing a

Applicants: Kenneth A. Jones, et al.
U.S. Serial No. 09/211,755
Filed: December 15, 1998
Page 16

pharmaceutically acceptable carrier and a pharmaceutically acceptable amount of a chemical compound identified by the process of any of claims 208, 213, or 224 or a novel structural and functional analog or homolog thereof.--

B1
--248. (New) A process for preparing a pharmaceutical composition which comprises admixing a pharmaceutically acceptable carrier and a pharmaceutically acceptable amount of a chemical compound identified by the process of any of claims 209, 215, or 226 or a novel structural and functional analog or homolog thereof.--

--249. (New) The process of any of claims 246, 247, or 248, wherein the GABA_aR1/R2 receptor is a human GABA_aR1/R2 receptor.--

REMARKS

Claims 1-17, 50, and 82 were pending in the subject application. By this Amendment applicants have canceled claims 1-17, 50, and 82 and added new claims 190-253. Accordingly, upon entry of this Amendment, claims 190-249 will be pending and under examination.

Applicants maintain the amendments to the specification and claims raise no issue of new matter and are fully supported by the specification. The amendments to the specification at page 19, 20 and 63 to include the appropriate sequence identifiers (SEQ ID NOS) are made to bring the specification of the subject application into compliance with 37 C.F.R. §1.821 through 1.825.

Applicants also submit herewith a formatted Sequence Listing in a computer readable form which complies with the requirements of 37 C.F.R. §1.824. In addition, applicants submit a Statement in